Baseline values and least squares mean changes from baseline at weeks 12 and 52 for SF-36 domain scores.
| Baseline mean (SD) | Week 12 LSM | Week 52 LSM | ||||||
| SF-36 domain scores | Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | Baricitinib (n=487) | Adalimumab (n=330) |
| Physical functioning | 32.4 (10.4) | 32.3 (10.2) | 31.6 (10.7) | 4.3 | 8.0***† | 6.8*** | 9.9† | 8.4 |
| Role physical | 36.3 (10.3) | 35.5 (10.3) | 34.5 (10.5) | 4.4 | 7.8*** | 6.7*** | 9.4†† | 7.5 |
| Bodily pain | 34.9 (7.7) | 34.6 (7.5) | 34.5 (8.5) | 4.6 | 9.1***† | 7.6*** | 11.2† | 9.7 |
| General health | 36.6 (8.6) | 37.3 (8.1) | 36.3 (8.7) | 3.1 | 5.4*** | 4.5††† | 6.1† | 4.8 |
| Vitality | 43.9 (10.1) | 43.8 (9.5) | 43.2 (10.5) | 3.9 | 6.4*** | 5.7††† | 7.9† | 6.6 |
| Social functioning | 41.3 (11.3) | 40.9 (11.6) | 40.0 (12.2) | 3.0 | 5.6*** | 4.4* | 6.6†† | 4.6 |
| Role emotional | 41.4 (12.5) | 41.4 (12.5) | 40.3 (12.9) | 3.7 | 5.1* | 4.8 | 6.6† | 5.3 |
| Mental health | 42.9 (11.3) | 43.3 (11.1) | 42.5 (11.5) | 3.7 | 4.0 | 3.9 | 5.1 | 4.4 |
*p≤0.05, **p≤0.01, ***p≤0.001 versus placebo.
†p≤0.05,††p≤0.01,†††p≤0.001 versus adalimumab.
LSM, least squares mean; SF-36, Short-Form-36.